11.80
-0.2001(-1.67%)
Currency In USD
| Previous Close | 12 |
| Open | 12 |
| Day High | 12 |
| Day Low | 11.8 |
| 52-Week High | 76 |
| 52-Week Low | 4.56 |
| Volume | 7,375 |
| Average Volume | 19,572 |
| Market Cap | 55.39M |
| PE | -3.92 |
| EPS | -3.01 |
| Moving Average 50 Days | 12.11 |
| Moving Average 200 Days | 12.15 |
| Change | -0.2 |
If you invested $1000 in MiNK Therapeutics, Inc. (INKT) since IPO date, it would be worth $98.33 as of January 14, 2026 at a share price of $11.8. Whereas If you bought $1000 worth of MiNK Therapeutics, Inc. (INKT) shares 3 years ago, it would be worth $497.89 as of January 14, 2026 at a share price of $11.8.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease
GlobeNewswire Inc.
Jan 08, 2026 5:00 PM GMT
Non-dilutive public-private funded trial with NIAID STTR & Mary Gooze Clinical Trial and Translation AwardExpands iNKT platform into transplantation with an off-the-shelf, HLA-independent, lymphodepletion-free experimental therapy in patients at risk
MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors
GlobeNewswire Inc.
Nov 20, 2025 4:42 PM GMT
MiNK-215, an IL-15 armoured FAP-targeting CAR-iNKT, targets and clears tumor-protective FAP+ fibroblasts to allow immune cells to infiltrate and kills cancer cellsActivates multiple immune pathways to generate potent, lasting anti-tumor activity in l
MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation
GlobeNewswire Inc.
Nov 14, 2025 12:30 PM GMT
New clinical data show durable remissions and long-tail survivors including >2-year complete remissions in chemotherapy- and checkpoint-refractory cancersGVHD trial launching through non-dilutive funding from NIH- and philanthropic grantsLaunching Ph